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Albumin-heparin microspheres were prepared by a two-step process which involved the preparation 
of a soluble albumin-heparin conjugate, followed by formation of microspheres from this conjugate or 
by a double cross-linking technique involving both coupling of soluble albumin and heparin and 
microsphere stabilization in one step. The first technique was superior since it allowed better control 
over the composition and the homogeneity of the microspheres. Microspheres could be prepared with 
a diameter of 5-35pm. The size could be controlled by adjusting the emulsification conditions. The 
degree of swelling of the microspheres was sensitive to external stimuli, and increased with increas- 
ing pH and decreasing ionic strength of the medium. 
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Conventional administration of drugs using simple 
drug dosage forms like tablets, capsules and bolus 
injections is not always optimal for effective treatment. 
In the last decade numerous drug delivery systems 
have been developed, giving better control over drug 
release rates and drug targeting. Among these novel 
drug delivery systems, microspheres take an important 
place. Microspheres have been prepared from a variety 
of synthetic and natural polymers14. 
Albumin microspheres (AMS) bave seen an extensive 
development during the past 20 years. AMS, loaded 
with cytotoxic agents such as adriamycin, have been 
widely investigated as possible chemoembolization 
device8”. These AMS are generally prepared by the 
formation of a water-in-oil emulsion and subsequent 
StabiIization of the protein droplets by using chemical 
cross-linking agents such as glutaraldehyde, formalde- 
hyde or 2,3-butadione, or by thermal denaturation of 
the protein. Problems encountered in the preparation 
of drug-loaded AMS are mainly related to the 
hydrophobicity of the AMS, and drug loading and 
release properties. Drug loading has to be done during 
the microsphere preparation process and chemical 
reactions with or thermal decomposition of the drug 
cannot always be prevented7*“. The in vitro drug 
release is generally considered to be biphasic. During 
the first phase a large amount of the drug may be 
released within a few minutes to hours. This initial 
large and fast release (i.e. the burst effect) is followed 
by a much slower, first-order releaseg. 
correspondence to Dr 1. Feijen. 
Albumin has an iso-electric point of 5.~~’ and under 
physiological conditions, AMS exert some ion- 
exchange properties, but these properties are too weak 
to be of interest. By the introduction of polyanions, 
however, the ion-exchange properties are increased 
and some of the disadvantages described above can be 
overcome. Microspheres prepared from albumin and 
polyanions are more hydrophilic and, together with 
the ion-exchange properties, this enables drug loading 
of ionic drugs after the preparation process. 
Previously, Longo et a1.7 have prepared ion-exchange 
albumin microspheres by incorporating poly(cc-L- 
glutamic acid] in the microspheres. Willmott et al.‘* 
prepared microspheres from albumin and poly(aspartic 
acid). 
In this paper the preparation and characterization of 
biodegradable ion-exchange microspheres containing 
albumin and heparin are described. These microspheres 
can be prepared by techniques similar to those used in 
the preparation of AMS. Previously, we have described 
a method” starting with a preformed albumin-heparin 
conjugateI and stabilization with glutaraldehyde (two- 
step procedure) giving albumin-heparin conjugate 
microspheres (AHCMS]. This method was evaluated 
more thoroughly, with regard to the influence of the 
cross-linking conditions on the swelling behaviour. 
Furthermore, another method is described in which 
the conjugate preparation step is omitted. These 
albumin-heparin microspheres (AHMS) can be 
prepared using a double cross-linking technique by 
stabilization of an aqueous mixture of albumin and 
heparin with l-ethyl-3-(3-dimethylaminopropyl)carbo- 
diimide (EDC) followed by glutaraldehyde. 
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MATERIALS AND METHODS 
Materials 
Human serum albumin was obtained from the Central 
Laboratory of the Dutch Red Cross Blood Trans~sion 
Service, Amsterdam, The Netherlands. Heparin from 
porcine intestinal mucosa, with a specific activity of 
165 IUlmg as indicated by the manufacturers, was 
obtained from Diosynth (Oss, The Netherlands). 
Cibracon Blue Sepharose (CBS) and Diethylaminoethyl 
(DEAE)-Scpharose 4B were obtained from Pharmacia 
Fine Chemicals (Uppsala, Sweden). Highly refined 
olive oil, porcine albumin (fraction V) and glutaralde- 
hyde (25% aqueous solution, grade I) were obtained 
from Sigma (St Louis, MO, USA). Glutaraldehyde 
(25% aqueous solution) was obtained from Merck 
(Darmstadt, Germany). Albumin-heparin conjugates, 
prepared from porcine albumin with heparin contents 
of 5.9% (p-AHCl), 16.0% (p-AH(X) and 21.5% (p- 
AHC3). as indicated by the manufacturer, were 
obtained from Holland Biomaterials Group (Enschede, 
The Netherlands). Phosphate buffered saline (PBS) was 
obtained from the NPBI (Emmer Compascuum, The 
Netherlands). All other reagents were obtained, in the 
highest possible grade, from Merck (Darmstadt, 
Germany). 
Glutaraldehyde purification 
As a result of aldol condensation reactions, commer- 
cially available glut~aldehyde solutions usually 
contain x&unsaturated dimers, trimers or higher 
oligomers’*. To remove these impurities, glutaralde- 
hyde solutions were purified by distillation at 13mm 
Hg, as described by Gillett and Gu11Y5. The fraction 
albumin 0 heparin 
a b 
distilling at 70-75°C was collected. The distilled glutar- 
aldehyde was dissolved in boiling water to obtain 1, 
2.5, 5 and 25% w/v aqueous solutions. The purified 
solutions were stored at 4°C. The UV spectrum of 
glutaraldehyde shows an absorption peak at 280nm, 
whereas the condensation products strongly absorb at 
235nm. Glutaraldehyde solutions were only used if 
the AZ35:Az80 ratio was lower than 0.4. 
Synthesis, purification and characterization of 
soluble conjugates of albumin and heparin 
The synthesis of the albumin-heparin conjugate was 
carried out by a slightly modified method of Hennink 
et a1.r3. Figure la shows a schematic representation of 
the conjugate synthesis and purification procedure. 
Albumin (12.5g) and heparin (3.75g) were dissolved 
in 175 ml of water. This solution was adjusted to pH 
5.0 with HCl (0.2 M). EDC (a solution of 1.24 g in 8 ml 
of water) was added dropwise to the reaction mixture 
over a period of 4 h at room temperature. Thirty 
minutes after the addition of EDC, the pH was adjusted 
to 7.6 with NaOH (1 M) and the mixture was gently 
stirred for 20 h at 4.C. Finally the solution was 
dialysed twice against 0.025 M Tris-HCl buffer, pH 7.5, 
using cellulose Visking” membranes. 
Unreacted heparin was removed from the reaction 
mixture using a CBS column. The column was equili- 
brated using CBS-equilibration buffer (0.17 M NaCll 
0.025 M Tris-HCl, pH 7.5). This buffer was also used to 
dissolve and load the conjugate/heparin/albumin 
mixture and to elute the heparin. The bound material 
(the conjugate and unreacted albumin) was eluted 
using CBS-elution buffer (1 M KSCN/0.025 M Tris-HCl, 
olive oil 
Figure1 Schematic representation of AHCMS preparation process: a, first step: AHC synthesis and purification/fractionat~on; 
b, second step: microsphere preparation from AHC using chemical stabilization with glutaraldehyde. 
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pH 7.5). The conductivity of the eluent was monitored 
using a conductivity cell (Philips, PW9513, cell 
constant = 1.66; Philips, Eindhoven, The Netherlands) 
connected to a conductivity meter (Philips PW9527 
digital conductivity meter; Philips). The protein 
content of the eluent was monitored on line using a 
UV-monitor (Single Path Monitor UV-1, Optical Unit 
and Control Unit; Pharmacia). Both monitors were 
connected to a double channel recorder (BD41; Kipp 
en Zonen, Delft, The Netherlands). Flow rates were 
controlled using a peristaltic pump (2132 Microperpex 
Peristaltic Pump; LKB, Uppsala, Sweden). After this 
purification step the eluted material was dialysed 
extensively against water and freeze dried. 
The unreacted albumin was removed using a DEAE 
column. The column was equilibrated with DEAE- 
equilibration buffer (0.3 M NaC110.025 M Tris-HCl, pH 
7.0). The albuminl~onjugate mixture was dissolved 
and loaded in 0.025M Tris-HCl, pH 7.0. Unreacted 
albumin was eluted using DEAE-equilibration buffer. 
Unfractionated purified conjugate (AHC) was obtained 
by elution with DEAE-elution buffer-I (0.9M NaCl/ 
0.025~ Tris-HCl, pH 7.0). After this purification step 
the AHC was dialysed extensively against water using 
cellulose Visking ” membranes and freeze dried. 
To obtain high af~nity conjugate (ha-AHC) the DEAE 
purification step was carried out using two elution 
buffers16. Loosely bound conjugate (low affinity 
conjugate) was first eluted using a buffer with a low 
ionic strength: DEAE-elution buffer-II (0.6 M NaCl/ 
0.025M Tris-HCl, pH 7.0). Subsequently, the ha-AHC 
was eluted using DEAE-elution buffer-I. 
The heparin content of the conjugate was determined 
using the metachromi~ assay described by Jacques and 
Wollin17, as modified by Hennink et ~1.‘~. The 
albumin content was determined using two methods, 
by UV/vis spectroscopy at 280nm and by a modified 
biuret method”. 
Microsphere preparation: two-step procedure 
Chemically stabilized AHCMS were prepared accord- 
ing to methods previously described for AMS”. This 
method for preparing the microspheres is outlined in 
Figure lb. 
To a flat-bottomed glass beaker (diameter 60mm, 
height 1lOmm) equipped with four baffles (depth 
4mm) positioned against the wall of the beaker was 
added 125ml of olive oil. A four-bladed axial-flow 
impeller, motor-driven using an IKA-RW20DZM 
mechanical stirrer (Janke & Kunkel, Staufen, Germany), 
was placed in the centre of the beaker with a 3mm 
distance between the baffles and the impeller blade. 
The impeller was submerged two thirds into the oil. 
After pre-stirring for 30 min at 850r.p.m., 0.6 ml of a 
conjugate solution in PBS (lOOmg/0.6ml PBS) was 
added dropwise from a syringe to the olive oil. After 
emulsification by stirring for an additional period of 
15min, 0.15ml of a glutaraldehyde solution of the 
desired concentration was added. The emulsion was 
then stirred at 850r.p.m. for 1 h to allow cross-linking 
of the albumin moieties. Subsequently 50ml of 
acetone was added and the emulsion was stirred for a 
further 10min. The microspheres were isolated by 
centri~gation for 15min at 27OOr.p.m., followed by 
decanting of the supernatant. The microspheres were 
then wasbed several times with acetone and finally 
dried in vacua at 50°C. 
To study the effect of (1) cross-link density, (2) 
reduction of the imines initially formed by the reaction 
of an aldehyde group with a primary amine group and 
(3) quenching of the unreacted aldehyde groups, 
several reaction conditions were varied. Cross-link 
density was varied by using glutaraldehyde solutions 
ranging from 1.0 to 25.0% w/v. Imines were reduced 
by the addition of 20 ~1 of an NaCNBHs solution (5 M) 
to the emulsion, prior to the addition of the glutaralde- 
hyde solution. Quenched AHCMS (AHCMSQ) were 
prepared by the addition of 100~1 of a 10% w/v 
aqueous glycine solution to the emulsion after cross- 
linking with glutaraldehyde. After addition of this 
solution, the emulsion was stirred for a further 1 h. 
Thermally stabilized microspheres (AHCMSmw) 
were prepared by heating the AHC solution/olive oil 
emulsion in a microwave oven (Toshiba ER 7700DW; 
Toshiba, Tokyo, Japan). After 15 min of emulsification 
as described above, the emulsion was equally divided 
into three 60ml glass bottles and placed in a 
microwave oven. The bottles were heated in three 
cycles (2 min- 1 min- 1 min) at full power (650 W). 
Between the cycles, the bottles were shaken to homo- 
genize the emulsion. After microwave treatment, the 
bottles were left to cool to room temperature. Then 
AHCMSmw were washed, dehydrated and dried as 
described above. After collection, the microspheres 
were washed to remove unbound material by ultraso- 
nic resuspension in 5ml of ethanol. PBS (45 ml) was 
added and the suspension was rotated for 30min. 
After centrifugation and decantation of the washing 
medium, 50ml of fresh PBS were added and the 
microspheres were washed once more. This procedure 
was repeated twice with distilled water. Microspheres 
were dehydrated with acetone and dried as described 
above. 
Microsphe~ p~paration: double cross-lining 
technique 
AHMS were also prepared from free albumin and 
heparin, using a double cross-linking technique 
(Figure 2). In these experiments, the same equipment 
was used as in the two-step procedure. A solution 
(0.4ml) of 100mg of albumin and 50mg of heparin in 
0.6 ml of water was added dropwise to 125 ml olive 
oil, pre-stirred for 30 min at 850 r.p.m. After emulsifica- 
tion for 15 min at 850r.p.m., 0.1 ml of 20% w/v EDC 
solution was added to couple the heparin to the 
albumin, After stirring for 4 h, 0.1 ml of an aqueous 
glutaraldehyde solution (25% w/v) was added for 
additional stabilization by cross-linking the albumin. 
The emulsion was stirred for a further 1 h. Micro- 
spheres were collected, washed and dried as described 
above. 
Particle size distribution of the microspheres 
The determination of the size and size distribution of 
the microspheres (n >250) was carried out using a 
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Figure 2 Schematic representation of AHMS preparation 
process: a solution of albumin and heparin is emulsified in 
olive oil, then EDC is added to couple albumin and heparin, 
and subsequently glutaraldehyde is added to stabilize the 
microspheres. 
scanning electron microscope (SEM) (JEOL JSM-35CF 
scanning electron microscope; JEOL, Tokyo, Japan) 
operated at 15 kV. For this purpose, a microsphere 
suspension in ethanol was dried on an aluminium 
chip and coated with a conducting gold layer using a 
Balzers Union Sputtering Device (Cathode Sputtering 
Unit 07 120; Balzers, Liechtenstein). Size distributions 
were also determined using a light microscope (LM) 
(Ortolux 2 POL-BK; Leitz, Wetzlar, Germany) fitted 
with a camera (Wild MPS52; Wild-Leitz, Heerburg, 
Switzerland) and a calibrated graticule. The SEM and 
LM micrographs were analysed using a particle size 
analyser (Carl-Zeiss, TG3). 
Swelling experiments 
The swelling behaviour of the microspheres was 
evaluated by measuring the mean diameter (2 = 
Cnidj/Cni) and the size distribution of the spheres 
(using two different techniques) in phosphate and 
citrate buffers of varying pH and ionic strength. 
In the first protocol, light microscopy was used to 
determine the size distribution of the microspheres. 
Microspheres (1 mg] were resuspended ultrasonically 
in 0.5 ml of ethanol. From this suspension, 10 samples 
of 25~1 were pipetted into separate wells of a 96-well 
microtitre plate. The ethanol was evaporated over- 
night, and subsequently 0.1 ml of buffer was added to 
the wells and the microspheres were resuspended 
ultrasonically in the buffers. Light microscopv pictures 
were taken, and the mean diameter and the size distri- 
bution of the microspheres was determined by image 
analysis techniques using a Quantimet 520 Plus 
morphometer (Leica, Rijswijk, The Netherlands). 
Swelling was also studied using a flow cytometer 
(FACStar+, Beckton-Dickinson, Mountain View, CA, 
USA). Microspheres (11 mg) were resuspended ultraso- 
nically in 1.1 ml of ethanol. From this suspension 
0.1 ml was pipetted into counting vials. To each 
counting vial, 0.9ml of buffer was added. To remove 
the ethanol from these solutions, the vials were centri- 
fuged, the supernatant was decanted and fresh buffer 
was added. The microspheres were resuspended in 
this buffer by vortexing. The mean diameter and the 
size distribution of the microspheres were determined 
using the FACStar’. Per sample, 10000 microspheres 
were counted. 
RESULTS AND DISCUSSION 
AHCMS were prepared from a prefabricated albumin- 
heparin conjugate by an emulsion stabilization techni- 
que. Since endogenous materials are used it is 
expected that the microspheres may be biocompatible 
as well as biodegradable. Due to the introduction of 
strong anionic groups by heparin incorporation, the 
microspheres will exert ion-exchange properties. 
Commercial glutaraldehyde solutions usually contain 
r&unsaturated oligomers and polymers. The presence 
of these compounds can be detected using UV spectro- 
scopy. Glutaraldehyde gives an absorption peak at 
280 nm, whereas the ~,~-unsaturated oligomers and 
polymers strongly absorb at 235nm. The impurities 
can be removed from the glutaraldehyde solutions by 
distillation or by multiple extraction with activated 
charcoal. Since distillation and subsequent dilution 
gives better control over the concentration of the final 
solution, this method was used. 
Figure 3 shows the UV spectra of two commercially 
available glutaraldehyde solutions and a purified 
solution. The high grade product, which is obtained in 
sealed ampoules under a nitrogen atmosphere, showed 
a small peak at 235 nm. The other commercial product, 
however, showed a much larger and broader peak in 
this region. After distillation of this product, this peak 
200 210 220 230 240 250 26x1 270 280 290 3Kl 
wavelength [nml 
Figure3 UV spectra of several glutaraldehyde solutions. 
0. Commercial 25% glutaraldehyde solution, Grade I, 
obtained in sealed ampoules under N2 atmosphere; 0, 
commercial 25% glutaraldehyde solution, normal grade; 
n , previous product after distillation (70-75”C, 13 mm Hg). 
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had disappeared completely, indicating removal of the 
a&unsaturated oligomers and polymers. After storage 
at 4°C for 2.5 years, some impurities had formed again, 
The solution, however, was used regularly during this 
period, undergoing warming up to room temperature. 
Solutions, continuously stored at 4X, did not show 
any changes in the W spectrum during this period. 
This is in agreement with the results of Gillett and 
GullI’, who showed that the formation of these impuri- 
ties is mainly determined by the storage temperature. 
Oxygen atmosphere and light did not seem to have any 
effect. Although the impurity of the normal grade 
commercial product seems substantial it should be 
taken into account that the polymer, absorbing at 
255nm, has a much higher extinction coefficient. 
Commerciaf products rarely contain more than 1% of 
the polymeric impurity”. 
After purification using CBS and DEAE-Sepharose 
column chromatography, the conjugate of albumin and 
heparin (AHC), containing 10.7 k 0.9% w/w of 
heparin, was prepared in a yield of about 50%. This is 
in good agreement with results obtained by Hennink 
et ~1.‘~. Fractionation of the conjugate was achieved 
using three different buffers during the DEAE purifica- 
tion step. The elution profile from the DEAE column is 
shown in Figure 4. The first two peaks refer to weakly 
bound material, mainly albumin, which was eluted 
using the DEAE equilibration buffer. The presence of 
two peaks is caused by the temporarily lower ionic 
strength due to the loading of the material onto the 
column using a buffer of lower ionic strength. This is 
confirmed by the dip in the conductivity curve. Using 
DEAE-elution buffer-II, loosely bound (low affinity) 
AHC was eluted (third peak). Subsequently, high 
affinity conjugate was eluted using DEAE-elution 
buffer-I (fourth peak). This procedure allowed the 
preparation of high affinity conjugate with a heparin 
content of 10.2 f 1.2% wlw in a yield of 35% based 
on the initial amount of albumin. 
Microspheres of albumin and heparin were prepared 
Table 1 Microsphere preparation conditions and results 
I II Jl 
I t I 
0 10 20 30 40 50 60 70 80 90 100 
fraction 
Figure4 Elution profile on DEAE-Sepharose 48. Initial 
buffer: 0.3~ NaCl/O.O25M Tris-HCI, pH 7.0; I: conjugate/ 
albumin solution in 0.025~ Tris-HCI, pH 7.0; II: 0.3M NaCI, 
0.025~ Tris-HCI, pH 7.0; III: 0.6~ NaCI, 0.025~ Tris-HCI, pH 
7.0; IV: 0.9~ NaCI, 0.025~ iris-HCI, pH 7.0: 0, conductiv- 
ity; l , absorbance. 
by the emulsion stabilization method. Under the 
applied emulsification conditions the diameter of 
glutaraldehyde cross-linked AHCMS was approxi- 
mately 5-35/1m. Cross-link density (i.e. the concentra- 
tion of the glutaraldehyde solution), reduction and 
quenching did not change the size distribution signifi- 
cantly (T&e 2). 
Figure 5 shows SEM micrographs of the AHCMSOS, 
of the ha-AHCMS50 and of the AHMS (prepared by 
the double cross-linking technique). From these 
micrographs it can be seen that AHCMSOS and AHMS 
had approximately the same size. AHMS, however, 
had a much more ruffled surface. This is indicative of 
matrix inhomogeneity which can be caused by a 
*phase separation’ of the polymer solution, favouring 
the presence of albumin at the oil-water interface, 
Code Material Stirring Stabilization Size* Yield’ 
heparin content 
(%I 
speed 
(r.p.m.) Glutaraldehyde 
(%I 
Reduction Quenching 
(pm) (%) 
AHCMSOZ 10.7 850 0.2 _ - 4-36 75 
AHCMSOS 10.7 850 0.5 _ - 5-35 72 
AHCMSlO 10.7 850 1.0 - _ 7-35 79 
AHCMSlOR 10.7 850 0.2 + _ 5-37 73 
AHCMSlOQ 10.7 850 1.0 - + 5-35 69 
AHCMSlORQ 10.7 850 1.0 + + 5-35 75 
ha-AHCMS& 10.2 1230 5.0 - - 12-80 76 
p-AMS$ 0.0 950 0.5 - - 2-18 73 
p-AHC1 MS” 5.9 950 0.5 - - 2-27 78 
p-AHC2MS” 16.0 950 0.5 - _ 2-27 79 
p-AHC3MS” 21.5 950 0.5 - - 3-60 78 
AHCMSmw’ 10.7 850 thermal 5-40 76 
AHMS” 33.3 850 EDCIS.O% - 4-30 50 
‘As determined from LM and SEM micrographs. 
‘Based on the initial amount of conjugate or albumin plus heparin. 
zMicrospheres prepared from the high affinity albumln-heparin conjugate fraction eluted from DEAE Column. 
‘Conjugates obtained from HBG, Enschede, The Netherlands, prepared from porcine albumin. p-AMS w?re prepared from porcine albumin obtained from Sigma. 
‘Microspheres prepared by thermal stabilization; stirring speed refers to initial emulsification conditions. 
“Microspheres prepared using the double cross-linking technique; heparin content refers to initial ratio of albumin and heparin in the SOfUtiOn. 
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Figure 5 SEM micrographs of microspheres prepared from 
albumin and heparin: a, AHCMSOS, prepared from AHC, 
cross-linked with 0.5% glutaraldehyde; b, ha-AHCMSSO, 
prepared from high-affinity AHC, cross-linked with 5.0% 
glutaraldehyde; c, AHMS, prepared from albumin and 
heparin using the double cross-linking technique. Bar 
indicates 10pm. 
resulting in an albumin-poor phase at the core of the 
droplet and an albumin-rich phase at the outside. This 
eventually results in a tightly cross-linked outer layer 
of the microspheres and a loosely stabilized core. 
During the washing procedure, the core material is 
removed and the microspheres collapse. Consequently 
the yield after washing of the AHMS was much lower 
than the yields obtained when the microspheres were 
prepared from the conjugates (Table 1). 
Micrograph analysis of the microspheres showed that 
the size distribution of the microspheres was 
influenced by the kind of conjugate used. Using the 
high affinity conjugate a more viscous aqueous 
solution was obtained. Assuming that the high affinity 
conjugate has more charged groups than the un~a~tion” 
ated conjugate, which would account for the high 
affinity towards the DEAE-Sepharose, the increased 
viscosity is a phenomenon often observed with 
polyelectrolyte solutions, which generally become 
more viscous with increasing degree of dissociation. 
However, the difference between high affinity 
conjugate and un~actionated conjugate may also be an 
increased mobility and chain length of the heparin 
moieties of the high affinity conjugate which in turn 
also would account for the increased viscosity of 
solutions of this material. In order to obtain 
microspheres of approximately the same diameter as 
microspheres prepared from an unfractionated 
conjugate, a higher stirring speed was applied. The 
size distribution determined, however, was broader: 
12-80pm. The influence of the viscosity of the 
aqueous phase on the size distribution of the spheres 
is also shown in Figures 6 and 7. 
Figure 6 shows the cumulative size distribution of p- 
AHCMS. With increasing heparin content, i.e. with 
increasing viscosity of the aqueous phase, the p- 
AHCMS became larger and the size distribution 
became broader. Figure 7 shows the size distributions 
of AHCMS prepared under different reaction 
conditions. Increasing the conjugate condensation of 
the aqueous phase resulted in larger microspheres. 
Figure 7 also shows the influence of increasing the 
amount of the aqueous phase. 
As already mentioned, the size of the microspheres 
increased with increasing amount of the aqueous 
phase. Burger et al.‘” showed that the diameter of AMS 
increased with increasing viscosity of the aqueous 
phase as well as with decreasing stirring speed, 
decreasing viscosity of the organic phase and increas- 
ing amount of aqueous phase. A number of essentially 
0 IO 20 30 40 50 
diameter [Km] 
Figure6 Cumulative size distributions of microspheres 
(n > 250) prepared from porcine albumin or porcine AHC 
with increasing heparin contents: II, p-AMS, 0, p- 
AHClMS, 5.9% heparin; 0, p-AHCPMS, 16.0% heparin; 0, 
p-AHC3MS, 21.5% heparin. 
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diameter [urn I 
Figure7 Cumulative size distributions of AHCMS 
(n > 250): [3, 1OOmg AHC dissolved in 0.6ml of aqueous 
phase, 0.4ml injected in olive oil; n , 100mg AHC dissolved 
in 0.6 ml of aqueous phase, 0.6 ml injected in olive oil; 0, 
100mg AHC dissolved in 0.4ml of aqueous phase, 0.4ml 
injected in olive oil. 
similar empirical relationships between average 
particle size and these parameters have been described 
in the literature on suspension polymerization. 
Equation 1 provides a qualitative guide for controlling 
the size of microspheres produced by that method. 
where d is the average droplet (particle) size; I( 
symbolizes parameters such as vessel design and type 
of stirrer: Dv is the diameter of the vessel: Ds is the 
diameter of the stirrer; R is the volume ratio of the 
droplet phase to suspension medium; N is the stirring 
speed; vd is the viscosity of the droplet phase; v, is the 
viscosity of the suspension medium; 7 is the surface 
tension between the two immiscible phases: and C, is 
the stabilizer concentration”. 
The colour of the microspheres was influenced by 
the glutaraldehyde concentration used to stabilize the 
microspheres. In the case of 1.0% glutaraldehyde 
cross-linking, the microspheres were yellow-brown. 
This colour became darker with increasing glutaralde- 
hyde concentration. Thermally stabilized microspheres 
as well as microspheres stabilized with 0.2% glutaral- 
dehyde were almost colourless. The colour of the 
microspheres was also influenced by reduction of the 
imine with NaCNB~~ during cross-linking. Micro- 
spheres cross-linked with 1.0% glutaraldehyde in the 
presence of this reducing agent had a colourless 
instead of a brown appearance. Quenching with 
glycine did not affect the colour. The colouring of the 
microspheres can be explained by the reactions 
involved in the cross-linking with glutaraldehyde. 
Although the exact cross-linking mechanism is not yet 
fully understood, it is generally accepted that the 
initial step is the formation of an imine by the reaction 
of an aldehyde grou 
1F: a lysine residuezzX2.. 
with a primary r-amine group of 
In the presence of a reducing 
agent like NaCNBH3, this group is readily converted to 
a stable secondary amine. Subsequently, the formation 
of a second amine may be followed by an intramolec- 
ular ring closing reaction. The resulting six membered 
imine is readily reduced by NaCNBH3 to give a piperi- 
dine ringz4. 
In the absence of the reducing agent, however, 
numerous subsequent reactions may occur, with the 
initial imine acting as an intermediate. These reactions 
may result in several types of oligomeric and 
polymeric cross-links, the most important being pyridi- 
nium corn ounds formed by oxidative cyclization of 
the iminegmz7. Some of the reaction products may 
account for the brown colourz8. Although polymeric 
cross-links consisting of up to 40 glutaraldehyde 
molecules have been described, it is more likely that 
only oligomeric cross-links are formed. Recently, Olde 
Damink” has shown that an average of three glutaral- 
dehyde molecules was consumed per reacted amine 
group in the cross-linking of collagen. 
In the case of thermal stabilization, different types of 
cross-links are formed. In the microwave oven, the oil 
was heated to 12OC. At these temperatures structural 
changes in the albumin are irreversible and stable 
microspheres are obtained by formation of intermolec- 
ular disulphide bridges between free cysteine SH 
groups on adjoining protein chains2,30. Sokoloski and 
Royer ” also report the formation of N-[Do-Z-amino-Z- 
c~boxy-ethyl)-L-lysine (lysinoalanine) cross-links; 
however, these authors do not explain the reaction 
mechanism of the formation of these cross-links. 
Compared with AMS, AHCMS are easily suspended 
in aqueous media. This may be explained by the way 
the particles are prepared. Widder et al.“’ hypohesize 
that the hydrophobicity of AMS is due to the apolar 
regions of the albumin aligning at the oil-water 
interface to form a hydrophobic crust. AHCMS, 
however, contain polyanionic heparin chains which 
may be exposed at the surface of the particles, increas- 
ing the hydrophilicity. 
ESCA studies of freeze dried AHCMS, data presented 
in Table 2, showed that sulphur was present at the 
surface, that the sodium content was increased and 
that the carbonoxygen ratio was decreased, implying 
that heparin is present at the surface of microspheres 
when contacted with water. Furthermore, AHCMS had 
a j potential of -40.0 mV as compared to -17 mV for 
AMS, which is also consistent with the presence of 
heparin entities at the surface”. 
The LM micrographs shown in Figure 8 demonstrate 
qualitatively the influence of the cross-link density 
Table 2 ESCA data for AMS and AHCMS* 
Sample Element Binding Atom % 
energy (eV) 
AMS C(ls) 
N(ls) 
O(ls) 
Na(2s) 
AHCMS Cfls) 
(freeze dried) N(ls) 
O(ls) 
S(2P) 
Na(2s) 
‘Data obtained from Kwon et a/.‘*. 
282 71.6 
396 8.9 
528 17.4 
61 1.7 
282 63.8 
396 a.1 
528 19.9 
168 0.6 
61 2.4 
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Figure 8 LM micrographs of AHCMSO2, AHCMSOS and AHCMSlO in the dry state, swollen in PBS at pH 7.4 and / = 0.17, and in 
distilled water. Bar indicates 50&m. 
and the medium on the swelling behaviour of AHCMS. Quantitative swelling data were obtained from the 
The LM experiments were not suitable for determina- flow cytometric measurements. In these experiments 
tion of quantitative effects of the cross-link density of 10 000 microspheres were counted to give size distribu- 
the particles and of the pH and ionic strength of the tions as shown in Figures 9 and 11. Figure 9 gives the 
swelling medium. This was due to the small number size distribution of AHCMSO5 as a unction of the pH 
of particles counted in these experiments [below 80). at an ionic strength of 0.4. With increasing pH, the size 
However, it can be seen that the degree of swelling in distribution became broader and shifted to higher 
distilled water was higher than in PBS. Figure 8 also values. This is also shown in Figure 10. The pH- 
demonstrates that the degree of swelling decreased dependent swelling behaviour of AHCMS can be 
with increasing glutaraldehyde cross-linking. explained by the ionization of functional groups of the 
10 
7 
PH 
micro-spheres 
diameter [pm] 
Figure9 Size distributions of AHCMS05 in buffers of varying pH at an ionic strength f = 0.4. Size distributions were 
determined using a flow cytometer; 10000 particles were counted. 
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Figure 10 Mean diameter of AHCMS as a function of the pH 
at ionic strength, I = 0.4: n , AHC~SO5: 17, AHCMSIO. Each 
point represents the mean diameter of 10000 
microspheres, as determined using a flow cytometer. 
albumin (Asp, Glu, Lys) and of the heparin (sulphate, 
sulphamate and carboxylate groups). An increase in 
negatively charged groups in the matrix leads to 
increased repulsive forces, resulting in expansion of 
the network. Such a pH-dependent swelling of 
polyelectrolyte gels has also been observed by Seigel 
and Firestone3’. 
Counterions in the network may effectively neutra- 
lize this repulsion and consequently decrease the 
swelling. So with increasing ionic strength the 
swelling should decrease, which is demonstrated in 
Figures 12 and 12. .F’igures 10 and 1.2 also show that 
the degree of swelling is influenced by the stabilization 
of the microspheres. At higher cross-link density, 
swelling is reduced, 
The effect of the NaCNBH3 reduction during the 
cross-linking is shown in Figure 13. This graph shows 
that the swelling ability of AHCMSlOR and 
AHCMSlORQ is reduced as compared with non- 
reduced microspheres. This may be caused by the 
reduction of the initially formed imines, which 
prevents the formation of oligomeric and polymeric 
glutaraldehyde cross-links. Another explanation is that 
Albumin-heparin microspheres: H.F.M. Cremers et al. 
in the presence of NaCNBH~, relatively hydrophobic 
piperidine compounds may be formed’*, shielding the 
amino groups, which also results in a decrease in the 
degree of swelling. Quenching with glycine did not 
influence the swelling behaviour of the microspheres. 
Previously, Kwon et ~1.~~ showed that AHCMS can be 
loaded with high molecular weight compounds by a 
swelling-deswelling process. The presence of heparin 
introduces ion-exchange properties, allowing the 
loading of microspheres with positively charged drugs 
like adriamycin3*. These findings suggest that AHCMS 
can be used as both swelling-controlled and ion- 
controlled drug delivery devices. 
CONCLUSIONS 
AHCMS can be prepared in a two-step procedure 
involving AHC synthesis and purification in the first 
step and microsphere preparation in the second step. 
AHMS can be prepared from albumin and heparin 
using a double cross-linking technique. The latter 
procedure, however, gives less control over the 
composition of the microspheres and is therefore not 
recommended. AHCMS are more hydrophilic than 
albumin microspheres, due to the presence of the 
heparin at the surface of the microspheres. This 
enables the suspension of AHCMS in the absence of 
surfactants which were necessary to stabilize albumin 
microsphere suspensions. The stimuli-sensitive- 
swelling behaviour of the microspheres allows loading 
of high molecular weight compounds, whereas the ion- 
exchange properties enable the loading of positively 
charged drugs. In conclusion, due to the improvement 
of the suspension properties and drug loading charac- 
teristics of albumin microspheres by the incorporation 
of another endogenous material, namely heparin, 
AHCMS have great potential as drug delivery devices. 
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cl 
Figure12 Mean diameter of AHCMS as a function of the 
ionic strength at pH 7.4: II, AHCMS05; 0, AHCMSIO. Each 
point represents the mean diameter of 10000 
microspheres, as determined using a flow cytometer. 
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Figure13 Mean diameter of AHCMS as a function of the pH 
at ionic strength, f = 0.4: lj, microspheres cross-linked with 
1.0% glutaraldehyde; a, microspheres cross-linked with 
1 .O% glutaraldehyde, subsequently quenched with glycine; 
0, microspheres cross-linked with 1% glutaraldehyde in 
the presence of NaCNBH3; 0, microspheres cross-linked 
with 1.0% glutaraldehyde in the presence of NaCNBH3, 
subsequently quenched with glycine. Each point represents 
the mean diameter of 10000 microspheres, as determined 
using a flow cytometer. 
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